FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158213441> ?p ?o ?g. }

• W2158213441 abstract "A number of biological agents are available or being investigated for the treatment of asthma and rhinitis. The safety profiles of these biologic agents, which may modify allergic and immunological diseases, are still being elucidated. Subcutaneous allergen immunotherapy, the oldest biologic agent in current use, has the highest of frequency of the most serious and life-threatening reaction, anaphylaxis. It is also one of the only disease modifying interventions for allergic rhinitis and asthma. Efforts to seek safer and more effective allergen immunotherapy treatment have led to investigations of alternate routes of delivery and modified immunotherapy formulations. Sublingual immunotherapy appears to be associated with a lower, but not zero, risk of anaphylaxis. No fatalities have been reported to date with sublingual immunotherapy. Immunotherapy with modified formulations containing Th1 adjuvants, DNA sequences containing a CpG motif (CpG) and 3-deacylated monophospholipid A, appears to provide the benefits of subcutaneous immunotherapy with a single course of 4 to 6 preseasonal injections. There were no serious treatment-related adverse events or anaphylaxis in the clinical trials of these two immunotherapy adjuvants. Omalizumab, a monoclonal antibody against IgE, has been associated with a small risk of anaphylaxis, affecting 0.09% to 0.2% of patients. It may also be associated with a higher risk of geohelminth infection in patients at high risk for parasitic infections but it does not appear to affect the response to treatment or severity of the infection. Clinical trials with other biologic agents that have targeted IL-4/IL-13, or IL-5, have not demonstrated any definite serious treatment-related adverse events. However, these clinical trials were generally done in small populations of asthma patients, which may be too small for uncommon side effects to be identified. There is conflicting information about the safety TNF-alpha blocking agents, which have been primarily used in the treatment of rheumatoid arthritis, with serious infections, cardiovascular disease and malignancies being the most frequent serious adverse events. An unfavorable risk-benefit profile led to early discontinuation of a TNF-blocking agent in a double-blind placebo controlled of severe asthmatics. In summary, the risk of anaphylaxis and other treatment-related serious events with of all of the biological agents in this review were relatively small. However, most of the clinical trials were done in relatively small patient populations and were of relatively short duration. Long term studies in large patient populations may help clarify the risk-benefit profile of these biologic agents in the treatment of asthma." @default.
• W2158213441 created "2016-06-24" @default.
• W2158213441 creator A5076736189 @default.
• W2158213441 date "2009-10-22" @default.
• W2158213441 modified "2023-09-27" @default.
• W2158213441 title "How safe are the biologicals in treating asthma and rhinitis?" @default.
• W2158213441 cites W1495964112 @default.
• W2158213441 cites W1910182345 @default.
• W2158213441 cites W1964354442 @default.
• W2158213441 cites W1972551310 @default.
• W2158213441 cites W1987965730 @default.
• W2158213441 cites W1990702493 @default.
• W2158213441 cites W1993375385 @default.
• W2158213441 cites W1993560650 @default.
• W2158213441 cites W1994585625 @default.
• W2158213441 cites W1996970629 @default.
• W2158213441 cites W1997120806 @default.
• W2158213441 cites W2004147651 @default.
• W2158213441 cites W2008039222 @default.
• W2158213441 cites W2009267110 @default.
• W2158213441 cites W2009608314 @default.
• W2158213441 cites W2010946738 @default.
• W2158213441 cites W2010998136 @default.
• W2158213441 cites W2017200913 @default.
• W2158213441 cites W2018589247 @default.
• W2158213441 cites W2020507548 @default.
• W2158213441 cites W2025111901 @default.
• W2158213441 cites W2029587541 @default.
• W2158213441 cites W2031035248 @default.
• W2158213441 cites W2033167631 @default.
• W2158213441 cites W2033559734 @default.
• W2158213441 cites W2034277352 @default.
• W2158213441 cites W2036694801 @default.
• W2158213441 cites W2041703033 @default.
• W2158213441 cites W2045356786 @default.
• W2158213441 cites W2060636831 @default.
• W2158213441 cites W2065204691 @default.
• W2158213441 cites W2065968680 @default.
• W2158213441 cites W2066962548 @default.
• W2158213441 cites W2070938229 @default.
• W2158213441 cites W2071324084 @default.
• W2158213441 cites W2071814570 @default.
• W2158213441 cites W2094852310 @default.
• W2158213441 cites W2097087514 @default.
• W2158213441 cites W2107207387 @default.
• W2158213441 cites W2110052844 @default.
• W2158213441 cites W2112571043 @default.
• W2158213441 cites W2125803815 @default.
• W2158213441 cites W2129689207 @default.
• W2158213441 cites W2131882149 @default.
• W2158213441 cites W2132372821 @default.
• W2158213441 cites W2135040670 @default.
• W2158213441 cites W2138766095 @default.
• W2158213441 cites W2145725835 @default.
• W2158213441 cites W2148583736 @default.
• W2158213441 cites W2153361994 @default.
• W2158213441 cites W2154986972 @default.
• W2158213441 cites W2159762698 @default.
• W2158213441 cites W2170599998 @default.
• W2158213441 cites W2170874916 @default.
• W2158213441 cites W2312829609 @default.
• W2158213441 cites W2325390361 @default.
• W2158213441 cites W2329314791 @default.
• W2158213441 cites W4211109829 @default.
• W2158213441 cites W4233594447 @default.
• W2158213441 cites W4235755338 @default.
• W2158213441 doi "https://doi.org/10.1186/1710-1492-5-4" @default.
• W2158213441 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2794848" @default.
• W2158213441 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20016776" @default.
• W2158213441 hasPublicationYear "2009" @default.
• W2158213441 type Work @default.
• W2158213441 sameAs 2158213441 @default.
• W2158213441 citedByCount "21" @default.
• W2158213441 countsByYear W21582134412012 @default.
• W2158213441 countsByYear W21582134412013 @default.
• W2158213441 countsByYear W21582134412015 @default.
• W2158213441 countsByYear W21582134412016 @default.
• W2158213441 countsByYear W21582134412020 @default.
• W2158213441 countsByYear W21582134412021 @default.
• W2158213441 countsByYear W21582134412023 @default.
• W2158213441 crossrefType "journal-article" @default.
• W2158213441 hasAuthorship W2158213441A5076736189 @default.
• W2158213441 hasBestOaLocation W21582134411 @default.
• W2158213441 hasConcept C126322002 @default.
• W2158213441 hasConcept C141105273 @default.
• W2158213441 hasConcept C159654299 @default.
• W2158213441 hasConcept C197934379 @default.
• W2158213441 hasConcept C203014093 @default.
• W2158213441 hasConcept C207480886 @default.
• W2158213441 hasConcept C2775933838 @default.
• W2158213441 hasConcept C2776042228 @default.
• W2158213441 hasConcept C2777701055 @default.
• W2158213441 hasConcept C2778564945 @default.
• W2158213441 hasConcept C2779787640 @default.
• W2158213441 hasConcept C2780510475 @default.
• W2158213441 hasConcept C535046627 @default.
• W2158213441 hasConcept C71924100 @default.
• W2158213441 hasConcept C8891405 @default.
• W2158213441 hasConceptScore W2158213441C126322002 @default.
• W2158213441 hasConceptScore W2158213441C141105273 @default.

• next